Drugs that contain Belumosudil Mesylate
1. List of Rezurock drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 16, 2028 |
NCE-1 date: July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic